Standout Papers

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease 2021 2026 2022 2024317
  1. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease (2021)
    Aaron B. Waxman, Ricardo Restrepo‐Jaramillo et al. New England Journal of Medicine

Immediate Impact

23 standout
Sub-graph 1 of 11

Citing Papers

Guidelines for the Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension: Recommendations from the American Society of Echocardiography
2025 Standout
Definition, classification and diagnosis of pulmonary hypertension
2024 Standout
2 intermediate papers

Works of Rahul Argula being referenced

Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE study
2024
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
2021 Standout
and 2 more

Author Peers

Author Last Decade Papers Cites
Rahul Argula 453 56 125 87 20 507
C. Billings 408 53 247 50 19 542
Bruno Dino Bodini 292 74 230 74 22 520
Davide Elia 368 92 81 177 33 521
DG Kiely 471 53 329 28 13 534
Nicla Campobasso 178 84 86 41 13 533
Vivien Chan 230 128 34 29 19 459
Fergall Magee 395 66 64 39 18 523
Irawan Susanto 323 212 34 51 21 458
Stergios Tassiopoulos 154 35 52 39 16 429
Kara Thompson 130 72 210 39 28 483

All Works

Loading papers...

Rankless by CCL
2026